Table 2.
The proportion of anticoagulant prescriptions by group of stratified cerebral infarction risk and bleeding risk.
| Year | 2011 | 2012 | 2013 | 2014 | 2015 | ||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Af | DOAC | VKA | Total | Af | DOAC | VKA | Total | Af | DOAC | VKA | Total | Af | DOAC | VKA | Total | Af | DOAC | VKA | Total | |||||||||||||||
| n | n | (%) | n | (%) | n | (%) | n | n | (%) | n | (%) | n | (%) | n | n | (%) | n | (%) | n | (%) | n | n | (%) | n | (%) | n | (%) | n | n | (%) | n | (%) | n | (%) | |
| 1 | 345 | 8 | (2.3) | 53 | (15) | 61 | (18) | 369 | 18 | (4.9) | 57 | (15) | 75 | (20) | 398 | 46 | (12) | 55 | (14) | 101 | (25) | 386 | 68 | (18) | 38 | (9.8) | 106 | (28) | 397 | 78 | (20) | 27 | (6.8) | 105 | (26) |
| 2 | 19 | 1 | (5.3) | 6 | (32) | 7 | (37) | 20 | 1 | (5.0) | 3 | (15) | 4 | (20) | 33 | 2 | (6.1) | 9 | (27) | 11 | (33) | 26 | 3 | (12) | 3 | (12) | 6 | (23) | 38 | 6 | (16) | 3 | (7.9) | 9 | (24) |
| Total (1 + 2) | 364 | 9 | (2.5) | 59 | (16) | 68 | (19) | 389 | 19 | (4.9) | 60 | (15) | 79 | (20) | 431 | 48 | (11) | 64 | (15) | 112 | (26) | 412 | 71 | (17) | 41 | (10) | 112 | (27) | 434 | 84 | (19) | 30 | (6.9) | 114 | (26) |
| 3 | 4233 | 146 | (3.4) | 1254 | (30) | 1400 | (33) | 4768 | 307 | (6.4) | 1485 | (31) | 1792 | (38) | 5079 | 718 | (14) | 1404 | (28) | 2122 | (42) | 5547 | 1279 | (23) | 1265 | (23) | 2544 | (46) | 5897 | 1706 | (29) | 1169 | (20) | 2875 | (49) |
| 4 | 3587 | 184 | (5.1) | 1738 | (49) | 1922 | (54) | 4058 | 337 | (8.3) | 1882 | (46) | 2219 | (55) | 4610 | 798 | (17) | 1898 | (41) | 2696 | (59) | 5211 | 1340 | (26) | 1895 | (36) | 3235 | (62) | 5745 | 1980 | (35) | 1792 | (31) | 3772 | (66) |
| Total (3 + 4) | 7820 | 330 | (4.2) | 2992 | (38) | 3322 | (43) | 8826 | 644 | (7.3) | 3367 | (38) | 4011 | (45) | 9689 | 1516 | (16) | 3302 | (34) | 4818 | (50) | 10,758 | 2619 | (24) | 3160 | (29) | 5779 | (54) | 11,642 | 3725 | (32) | 2991 | (26) | 6716 | (58) |
Group 1: CHA2DS2-VASc = 1, HAS-BLED = 1, 2; Group 2: CHA2DS2-VASc = 1, HAS-BLED ≧ 3; Group 3: CHA2DS2-VASc ≧ 2, HAS-BLED = 1,2; Group 4: CHA2DS2-VASc ≧ 2, HAS-BLED ≧ 3.
*Af Atrial fibrillation.
†VKA Vitamin K antagonist.
‡DOAC direct oral anticoagulant.
§CHA2DS2-VASc score heart failure, hypertension, age ≥ 75 years (doubled), diabetes mellitus, prior cerebral infarction or TIA (doubled), vascular disease, age 65–74 years, female sex.
||HAS-BLED score hypertension, kidney dysfunction, liver dysfunction, prior cerebral infarction or TIA, prior bleeding or predisposition to bleeding, age ≥ 65 years, use of AP and NSAIDs, alcoholism.
#NSAIDs non-steroidal anti-inflammatory drugs.
**TIA transient ischemic attack.